From bench to bedside: mGluR2 positive allosteric modulators as medications to treat substance use disorders.
Psychopharmacology (Berl)
; 234(9-10): 1347-1355, 2017 05.
Article
em En
| MEDLINE
| ID: mdl-27995279
ABSTRACT
OBJECTIVE:
This paper provides an overview of the role of type 2 metabotropic glutamate receptors (mGluR2) in addiction and behaviors reflecting addictive processes.RESULTS:
AZD8529, an mGluR2 positive allosteric modulator (PAM), failed to separate from placebo in a phase II schizophrenia trial. The demonstration by Athina Markou's laboratory that AZD8529 attenuated both nicotine self-administration and cue-induced reinstatement was a key factor in the decision to move this compound into a smoking cessation study.CONCLUSION:
Here, we highlight Markou laboratory's contribution to this project, as well as several innovative features of the phase II clinical trial that has already completed enrollment with top line results expected in early 2017.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Oxidiazóis
/
Receptores de Glutamato Metabotrópico
/
Transtornos Relacionados ao Uso de Substâncias
/
Dispositivos para o Abandono do Uso de Tabaco
/
Indóis
Tipo de estudo:
Clinical_trials
/
Prognostic_studies
Limite:
Animals
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article